Evaluation of safety and pharmacokinetics of bismuth‐containing quadruple therapy with either vonoprazan or lansoprazole for Helicobacter pylori eradication
British Journal of Clinical Pharmacology2021Vol. 88(1), pp. 138–144
Citations Over TimeTop 10% of 2021 papers
Ki Young Huh, Hyewon Chung, Yu Kyong Kim, SeungHwan Lee, Siddharth Bhatia, Yohei Takanami, Ryou Nakaya, Kyung‐Sang Yu
Abstract
The systemic exposure of bismuth was similar between vonoprazan- and lansoprazole-containing quadruple therapy. Vonoprazan-containing quadruple therapy was safe and well tolerated.
Related Papers
- Dual therapy with lansoprazole and clarithromycin for eradication of Helicobacter pylori.(1995)
- → Eradication of Helicobacter pylori with Lansoprazole and Clarithromycin in Gastric Ulcer Patients(1995)7 cited
- → Eradication of Helicobacter pylori with lansoprazole and clarithromycin(1995)26 cited
- → Efficacy of Lansoprazole in Eradication of Helicobacter pylori(1995)13 cited
- Pharmacokinetics study of lansoprazole for injection in Chinese healthy volunteers(2011)